Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q2 EPS of ($0.39), $0.03 worse than the analyst estimate of ($0.36).

For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.